Elaine Gilmore, MD
Dermatology · Fairport, NYNPI 1679778666
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (54.3%), food and beverage and grants — rather than concentrated in one kind of arrangement. Helsinn Healthcare SA accounts for 63.8% of it on its own, with 28 other manufacturers making up the rest. Reporting peaked in 2019 at $6,411 and has fallen 76.9% since, to $1,481 in 2025.
Across 222 payments — averaging $60.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Helsinn Healthcare SA$9K
- Johnson & Johnson$653
- Lilly USA, LLC$541
- AbbVie$504
- Novartis$488
- Pfizer$456
- plus $2K from 23 others
What the payments were for
- Consulting fees$200%
- Grants$8927%
- Travel & lodging$7,34154%
- Food & beverage$4,96637%
- Education$3032%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Helsinn Healthcare SA | 15 | $8,629 |
| Johnson & Johnson | 21 | $653 |
| Lilly USA, LLC | 21 | $541 |
| AbbVie | 29 | $504 |
| Novartis | 17 | $488 |
| Pfizer | 31 | $456 |
| Sun Pharmaceutical Industries Inc. | 15 | $454 |
| Incyte Corporation | 6 | $379 |
| Janssen Scientific Affairs, LLC | 3 | $197 |
| Bristol Myers Squibb | 2 | $164 |
| UCB, Inc. | 6 | $159 |
| Stemline Therapeutics Inc. | 1 | $139 |
| Amgen | 5 | $133 |
| Galderma Laboratories, L.p. | 5 | $93 |
| Prugen, Inc. Pharmaceuticals | 19 | $76 |
| Dermavant Sciences, Inc. | 3 | $69 |
| Organon | 7 | $60 |
| Sanofi | 2 | $55 |
| Kyowa Kirin, Inc. | 3 | $49 |
| Arcutis Biotherapeutics, Inc. | 2 | $39 |
| Sandoz | 1 | $26 |
| Regeneron Healthcare Solutions, Inc. | 1 | $24 |
| Almirall LLC | 1 | $24 |
| Dermira, Inc. | 1 | $23 |
| Mallinckrodt Enterprises LLC | 1 | $23 |
| LEO Pharma Inc. | 1 | $19 |
| Paratek Pharmaceuticals, Inc. | 1 | $18 |
| Springworks Therapeutics, Inc. | 1 | $15 |
| Helsinn Therapeutics (U.S.), Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$13,521 in reported general payments places this provider in the 80th percentile of 1,151 dermatology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TremfyaGuselkumab | 13 | $82,166 |
| Dupixent PenDupilumab | 13 | $46,276 |
| Clobetasol Propionate | 240 | $9,161 |
| Tacrolimus | 18 | $2,408 |
| Triamcinolone Acetonide | 181 | $2,316 |
| Metronidazole | 54 | $2,127 |
| Doxycycline Hyclate | 139 | $1,649 |
| Fluorouracil | 25 | $1,618 |
| Ketoconazole | 76 | $1,534 |
| MethotrexateMethotrexate Sodium | 60 | $1,477 |
| Betamethasone Dipropionate | 26 | $1,377 |
| Mycophenolate Mofetil | 16 | $1,353 |
| Clindamycin Phosphate | 28 | $834 |
| Nystatin | 58 | $616 |
| Hydrocortisone | 68 | $493 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonTremfya | $653 | $82,16613 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,151 dermatology providers in New York.
Other dermatology in Fairport
- Brian PoligoneFairport$343K
- Alexandra GolantNew York$3.6M
- David CohenNew York$3M
- Michael CameronNew York$2.6M
- Saakshi KhattriNew York$2.4M
- Amy WechslerNew York$2.4M
- Jeffrey WeinbergKew Gardens$2.3M
- Joshua ZeichnerNew York$2.1M
- Russell CohenOceanside$2.1M
- Jeffrey LaducaAuburn$1.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.